Oxytocin vs PT-141
One is FDA-approved for a single narrow sexual-desire indication; the other is a famous hormone whose most-cited behavioral findings largely failed to replicate.
Oxytocin
The 'bonding hormone' has a huge human literature — but its famous trust and behavior findings largely failed to replicate; approved only as injectable Pitocin for labor, not for the marketed claims.
Full Oxytocin evidence reviewPT-141
Bremelanotide / Vyleesi
FDA-approved as Vyleesi for HSDD in premenopausal women, with phase-3 evidence — but the off-label use in men and at higher doses goes beyond what's proven.
Full PT-141 evidence reviewSide by side
| Oxytocin | PT-141 | |
|---|---|---|
| Marketed for | Bonding, libido, mood (compounded sprays) | Libido, sexual dysfunction |
| Evidence grade | Clinical data | FDA-approved |
| Family | Sexual / melanocortin | Sexual / melanocortin |
| Regulatory status | FDA-approved | FDA-approved |
| How it's obtained | Rx product | Compounded |
| Key human source | Sikich autism RCT, NEJM 2021 | RECONNECT phase 3, Obstet Gynecol 2019 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
PT-141 (bremelanotide, Vyleesi) is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women, supported by two placebo-controlled phase 3 trials, though independent re-analysts call the magnitude modest and it carries nausea, flushing, headache, a transient blood-pressure rise, and possible focal hyperpigmentation. Oxytocin is approved only as intravenous Pitocin for labor induction and postpartum bleeding; the intranasal sprays sold for bonding, mood, and libido are off-label, the trust effect that made it famous proved fragile, and the largest autism randomized trial was negative. The two have never been compared directly, and PT-141's approval does not extend to men or to general libido use.
Oxytocin fits if
Oxytocin is the more instructive read for someone who wants a case study in how a huge human literature can fail to replicate.
PT-141 fits if
PT-141 is relevant only to its approved population, premenopausal women with acquired, generalized HSDD, and under medical supervision.
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Oxytocin availability before ordering.
